替格瑞洛杂质A Ticagrelor impurity A 替格瑞洛杂质B Ticagrelor impurity
B 替格瑞洛杂质F Ticagrelor impurity F 替格瑞洛杂质G Ticagrelor
impurity G No.220347-05-7 替格瑞洛杂质L Ticagrelor Impurity L
替格瑞洛杂质M Ticagrelor impurity M No.274693-39-9 替格瑞洛杂质N
Ticagrelor impurity N 替格瑞洛相关化合物 Ticagrelor Related Compound
替格瑞洛相关化合物1 Ticagrelor Related Compound 1 No.155899-66-4
替格瑞洛相关化合物2 Ticagrelor Related Compound 2 No.592533-90-9
替格瑞洛相关化合物3 Ticagrelor Related Compound 3 No.88756-83-6
替格瑞洛相关化合物4 Ticagrelor Related Compound 4 No.1446475-48-4
替格瑞洛相关化合物5 Ticagrelor Related Compound 5 No.1414348-35-8
替格瑞洛相关化合物6 Ticagrelor Related Compound 6 HCl No.1345413-20-8 (free
base) 替格瑞洛相关化合物7 Ticagrelor Related Compound 7 No.63312-86-4
替格瑞洛相关化合物8 Ticagrelor Related Compound 8 No.378236-67-0
替格瑞洛相关化合物9 Ticagrelor Related Compound 9 替格瑞洛相关化合物10 Ticagrelor
Related Compound 10 替格瑞洛相关化合物12 Ticagrelor Related Compound 12
替格瑞洛相关化合物13 Ticagrelor Related Compound 13 替格瑞洛相关化合物14
Ticagrelor Related Compound 14 替格瑞洛相关化合物15 Ticagrelor Related Compound
15 替格瑞洛相关化合物16 Ticagrelor Related Compound 16 No.N/A
替格瑞洛相关化合物17 Ticagrelor Related Compound 17 No.N/A
替格瑞洛相关化合物18 Ticagrelor Related Compound 18 No.N/A
替格瑞洛相关化合物19 Ticagrelor Related Compound 19 No.N/A
替格瑞洛相关化合物20 Ticagrelor Related Compound 20 No.N/A
替格瑞洛相关化合物21 Ticagrelor Related Compound 21 No.N/A
替格瑞洛相关化合物22 Ticagrelor Related Compound 22 替格瑞洛相关化合物23
Ticagrelor Related Compound 23 替格瑞洛相关化合物24 Ticagrelor Related Compound
24 替格瑞洛相关化合物25 Ticagrelor Related Compound 25 替格瑞洛相关化合物26
Ticagrelor Related Compound 26 替格瑞洛N-葡糖苷酸 Ticagrelor
N-Glucuronide No.N/A 替格瑞洛O型葡糖苷酸 Ticagrelor O-Glucuronide
No.N/A 用途 ：药品申报检测,并提供COA、HPLC、MS、NMR等资料。 深圳卓越生物科技有限公司为您提供新药检测及申报用 原研参比制剂（一次性进口），EP、USP、BP、CP、JP、IP 、RC、TLC、MC 、sigma等近100个国外品牌的标准品和杂质对照品，同时优势提供国内杂质定制合成服务。可提供一次性进口服务、清关、准备资料以及开具原产地证明等。 现货供应头孢替安、头孢地尼、头孢他啶、西那卡塞、尼达尼布、依折麦布、乐伐替尼、瑞戈非尼、法舒地尔、达泊西罗库溴铵、依匹哌唑、伊格列净、卡格列净/坎格列净、达格列净、依帕列净、雷诺嗪、沃替西汀、帕沙康唑、阿普斯特、达比加群酯、阿格列汀、利格列汀、达帕西汀等标准品及其杂质对照品、质量标准。 联系人：郭生 联系电话：0755-23051186 www.ex-biotech.com 提示：本产品只用于研发和生产！
查看详情
生产公司：AstraZeneca Pharmaceuticals LP
商品名：BRILINTA
中文名称：替格瑞洛片
英文名称：ticagrelor tablets
剂型：tablets
规格：60mg*14 tabs
上市国：USA
数量：15+10+10 BOXES
仅供实验室使用
深圳卓越生物科技有限公司(http://www.chemdrug.com/company/)为您提供新药(http://www.chemdrug.com/)检测(http://www.chemdrug.com/sell/76/)及申报用 原研参比制剂（一次性进口），EP、USP、BP、CP、JP、IP 、RC、TLC、MC 、sigma等近100个国外品牌的标准品(http://www.chemdrug.com/sell/20/)和杂质对照品(http://www.chemdrug.com/sell/20/)，同时优势提供国内杂质定制合成(http://www.chemdrug.com/article/8/)服务以及优惠清关服务。
联系人：郭生
联系电话：0755-23051186
www.ex-biotech.com
提示：本产品(http://www.chemdrug.com/invest/)只用于研发和生产！
查看详情
生产公司：AstraZeneca AB商品名：Brilique中文名称：替格瑞洛分散片英文名称：Tigrilol orodispersible tablets剂型：orodispersible tablets规格： 90 mg *56上市国：UK数量：1Box仅供实验室使用
查看详情
替格瑞洛 Ticagrelor替格瑞洛杂质A Ticagrelor Impurity A替格瑞洛杂质B Ticagrelor Impurity B替格瑞洛杂质C Ticagrelor Impurity C替格瑞洛杂质D Ticagrelor Impurity D替格瑞洛杂质E Ticagrelor Impurity E替格瑞洛杂质F Ticagrelor Impurity F替格瑞洛杂质G Ticagrelor Impurity G替格瑞洛杂质H Ticagrelor Impurity H替格瑞洛杂质I Ticagrelor Impurity I替格瑞洛杂质J Ticagrelor Impurity J替格瑞洛杂质K Ticagrelor Impurity K替格瑞洛杂质L Ticagrelor Impurity L替格瑞洛杂质M Ticagrelor Impurity M替格瑞洛杂质N Ticagrelor Impurity N规格：10mg/25mg/50mg/100mg用途：供新药研究或实验使用结构式：现货供应，提供COA及结构确证图谱等。纯度：99%更多相关信息请来电或在线咨询卓越生物全面提供药物杂质对照品、标准品、原研药参比剂、转基因产品。旗下公司代理LGC、Cerlliant、EP、TRC、TLC、MC、JP、中检所、USP、AOCS等数十个品牌。卓越生物同时为您新药开发提供全方位的咨询服务！联系方式：许先生电话: 18025856141qq: 3001373991
查看详情
序号名称CAS化学名称结构式1替格瑞洛杂质ANA(1R,2R,3S,5R)-3-(7-(((1S,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 2替格瑞洛杂质BNA(1R,2R,3S,5R)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 3替格瑞洛杂质CNA(1S,2S,3R,5S)-3-(7-(((1S,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 替格瑞洛杂质DNA2-(((3aR,4S,6R,6aS)-6-((3-((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol 4替格瑞洛杂质ENA(1S,2S,3R,5S)-3-((3-((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)amino)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 5替格瑞洛杂质FNA2-(((1S,2S,3S,4R)-4-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,3-dihydroxycyclopentyl)oxy)ethyl acetate 6替格瑞洛杂质GNA(1S,2R,3S,4R)-4-(7-(((1S,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)cyclopentane-1,2,3-triol 7替卡格雷杂质 HNA(1S,2S,3R,5S)-3-(7-amino-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 8替卡格雷杂质 INA(1S,2S,3R,5S)-3-(7-hydroxy-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 9替卡格雷杂质 JNA(1S,2S,3R,5S)-3-((5-amino-6-chloro-2-(propylthio)pyrimidin-4-yl)amino)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 10替卡格雷杂质 KNA(1S,2S,3R,5S)-3-(7-chloro-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 11替卡格雷杂质 L（亚砜）NA(1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylsulfinyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 12替卡格雷杂质M(砜)NA(1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylsulfonyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 13替卡格雷杂质 NNA(1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 14替卡格雷杂质 ONA(1S,2S,3S,5S)-3-((6-chloro-5-((3-((1S,2S,3S,4S)-2,3-dihydroxy-4-(2-hydroxyethoxy)cyclopentyl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)amino)-2-(propylthio)pyrimidin-4-yl)amino)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 15替卡格雷杂质 PNA(1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3-fluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 16替卡格雷杂质 QNA(1R,2R,3S,5R)-3-(4-(((1R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-6-(propylthio)-1H-[1,2,3]triazolo[4,5-d]pyrimidin-1-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol compound with (1R,2R,3S,5R)-3-(4-(((1S,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-6-(propylthio)-1H-[1,2,3]triazolo[4,5-d]pyrimidin-1-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol (1:1) 17替卡格雷杂质 RNAD-酒石酸盐； cis-2-(3,4-difluorophenyl) cyclopropanamine2-(((3aS,4R,6S,6aR)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol 18替卡格雷杂质 SNAbenzyl ((3aR,4S,6R,6aS)-6-(2-hydroxyethoxy)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)carbamate 19替卡格雷杂质 TNA(1S,2R)-2-(3,4-difluorophenyl)cyclopropanamine hydrochloride 20替卡格雷杂质 UNAtert-butyl ((1S,2R)-2-(3,4-difluorophenyl)cyclopropyl)carbamate compound with benzyl ((3aR,4S,6R,6aS)-6-(2-hydroxyethoxy)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)carbamate (1:1) 21替卡格雷杂质 VNA2-(((3aR,4S,6R,6aS)-6-((6-chloro-5-nitro-2-(propylthio)pyrimidin-4-yl)amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol 22替卡格雷杂质 WNA(1S,2R,3S,4S)-4-(7-chloro-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)cyclopentane-1,2,3-triol 23替卡格雷杂质 XNA环丙胺片段为（S,S），（R,R）混合物(1S,2S,3R,5S)-3-(7-(((1R,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol compound with (1S,2S,3R,5S)-3-(7-(((1S,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol (1:1) 24替卡瑞洛杂质 Y376608-65-02-(((3aS,4R,6S,6aR)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol (2R,3R)-2,3-dihydroxysuccinate25替卡格雷杂质 ZNA(1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylsulfinyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 26替卡格雷工艺中间体杂质1NA2-(((3aR,4S,6R,6aS)-6-((5-amino-6-chloro-2-(propylthio)pyrimidin-4-yl)amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol 27替卡格雷工艺中间体杂质2NA2-(((3aR,4S,6R,6aS)-6-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol 28替卡格雷工艺中间体杂质3NA2-(((3aR,4S,6R,6aS)-6-((6-chloro-5-nitro-2-(propylthio)pyrimidin-4-yl)amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol 29替格瑞洛杂质中间体1脱保护杂质1354945-69-9(1S,2S,3R,5S)-3-((5-amino-6-chloro-2-(propylthio)pyrimidin-4-yl)amino)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 30替卡格雷APINA(1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 31替卡格雷－im ANA(1S,2R)-2-(3,4-difluorophenyl)cyclopropanamine 32替卡格雷－im B(外消旋体)NA(1S,2S)-2-(3,4-difluorophenyl)cyclopropanamine 33替卡格雷－im CNA(1R,2S)-2-(3,4-difluorophenyl)cyclopropanamine 34替卡格雷－im DNA(1R,2S)-2-(3,4-difluorophenyl)cyclopropanamine hydrochloride 35替卡格雷－im ENA1-((1R,2R)-2-(3,4-difluorophenyl)cyclopropyl)-3-((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)urea 36替卡格雷－im FNA1,3-bis((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)urea
查看详情
供应杂质对照品～奥司他韦，地氯雷他定，氯雷他定，阿格列汀，利奈唑胺，曲格列汀，阿伐那非，帕瑞昔布钠，替格瑞洛，阿哌沙班，利伐沙班，阿考替胺，沃诺拉赞，利格列汀，维格列汀，替格列汀，沙酚酰胺，沙格列汀，安奈格列汀，lcz696，托法替布，达比加群酯，帕布昔利布，依匹哌唑，沃替西汀，泊康沙唑，雷美替胺，依折麦布，阿齐沙坦，盐酸溴己新，氨溴索，左甲状腺素钠，达克罗宁，匹多莫德，伊班磷酸钠，阿普斯特，埃索镁拉唑钠，乐伐替尼，马昔替坦，非布司他，奥美拉唑，兰索拉唑，泊马度胺，瑞替加滨，恩格列净，伊格列净，左西替利嗪，来那度胺，泊马度胺
查看详情
供应杂质对照品～奥司他韦，地氯雷他定，氯雷他定，阿格列汀，利奈唑胺，曲格列汀，阿伐那非，帕瑞昔布钠，替格瑞洛，阿哌沙班，利伐沙班，阿考替胺，沃诺拉赞，利格列汀，维格列汀，替格列汀，沙酚酰胺，沙格列汀，安奈格列汀，lcz696，托法替布，达比加群酯，帕布昔利布，依匹哌唑，沃替西汀，泊康沙唑，雷美替胺，依折麦布，阿齐沙坦，盐酸溴己新，氨溴索，左甲状腺素钠，达克罗宁，匹多莫德，伊班磷酸钠，阿普斯特，埃索镁拉唑钠，乐伐替尼，马昔替坦，非布司他，奥美拉唑，兰索拉唑，泊马度胺，瑞替加滨，恩格列净，伊格列净，左西替利嗪，来那度胺，泊马度胺
查看详情
替格瑞洛（替卡格雷，Ticagrelor）原料及片剂 【化学名】替格瑞洛，又名替卡格雷（Ticagrelor） 【商品名】Brilinta 结构式： 【剂型及规格】片剂，90mg/片【注册分类】化药3+4 【适应症】用于减少急性冠脉综合征（ACS）患者的心血管死亡和心脏病发作替格瑞洛临床优势 1.抗血小板作用具有可逆性 替格瑞洛快速起效，快速消退的特性，在手术前72小时停药就可安全实施CABG，替格瑞洛成为接受搭桥手术患者首选药物。 2.具有非血小板介导的作用 能够提高血液腺苷浓度，改善心肌血供，降低心梗面积 3.较氯吡格雷起效更迅速 直接作用于ADP受体，不经肝代谢，不受体内代谢影响，起效时间为30分钟。抢救ACS患者有着突出的优势。 4.较氯吡格雷抗血小板作用更强、更持久 维持期，血小板抑制作用更强， 适合急性冠状动脉综合征患者长期使用。 5.较氯吡格雷进一步降低主要终点事件 替格瑞洛是首个能降低冠心病患者整体死亡率达22％的抗血小板药，并适用于同时患有糖尿病等其他疾病的患者。联系人：赵经理 13651360576 13522399152 bjrichcentre@sina.com
查看详情
扫码二维码，添加我的企业微信
X
违禁品提示！
XX
根据相关法律法规、政策，该产品禁止销售。
药智官方微信
药智官方微博
